Phase I Study of Extended Treatment Schedules of Oral Azacitidine for Patients with MDS, CMML or AML


Phase I Study of Extended Treatment Schedules of Oral Azacitidine for Patients with MDS, CMML or AML
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with Guillermo Garcia-Manero, MD (1/12/11)

Garcia-Manero G et al. Evaluation of oral azacitidine using extended treatment schedules: A Phase I study. Proc ASH 2010;Abstract 603.

Dr Garcia-Manero is Associate Professor of Medicine and Chief of the Leukemia Department’s Section of Myelodysplastic Syndromes at The University of Texas MD Anderson Cancer Center in Houston, Texas.